**Abstract.** Sleep disorder is confirmed as a core component of Alzheimer’s disease (AD), while the accumulation of amyloid β (Aβ) in brain tissue is an important pathological feature of AD. However, how Aβ affects AD-associated sleep disorder is not yet well understood. In the present study, experiments on animal and cell models were performed to detect the association between sleep disorder and Aβ. It was observed that Aβ25‑35 administration significantly decreased non‑rapid eye movement sleep, while it increased wakefulness in mice. In addition, reverse transcription‑quantitative polymerase chain reaction and western blot analysis revealed that the expression levels of tau, p‑tau, orexin A and orexin neurons express adenosine A1 receptor (A1R) were markedly upregulated in the brain tissue of AD mice compared with that in samples obtained from control mice. Furthermore, the in vitro study revealed that the expression levels of tau, p‑tau, orexin A and adenosine A1R were also significantly increased in human neuroblastoma SH‑SY5Y cells treated with Aβ25‑35 as compared with the control cells. In addition, the tau inhibitor TRx 0237 significantly reversed the promoting effects of Aβ25‑35 on tau, p‑tau, orexin A and adenosine A1R expression levels, and adenosine A1R or orexin A knockdown also inhibited tau and p‑tau expression levels mediated by Aβ25‑35 in AD. These results indicate that Aβ and tau may be considered as novel biomarkers of sleep disorder in AD pathology, and that they function by regulating the expression levels of orexin A and adenosine A1R.

**Introduction**

As a neurodegenerative disease, Alzheimer’s disease (AD) accounts for 50‑70% of all dementia cases. With the aging of the population, it is expected that the worldwide prevalence of AD will quadruple by 2050 as compared with the reported rate of 26.6 million cases in 2006, and ~43% of AD patients require a high level of care (1). The main symptoms of AD patients include cognitive decline, accompanied by psychological and behavioral abnormalities, decline in the ability to perform daily activities, depression and sleep disorder. As one of the common symptoms, sleep disorder severely affects the quality of life of patients (2).

AD‑associated sleep disorder is increasingly prominent, and studies on mechanism of AD‑associated sleep disorder and new therapies are of great value. However, the molecular mechanism of AD‑associated sleep disorder remain unclear. Kondratova and Kondratov (3) have suggested that the sleep disorder in patients with AD may be associated with the degeneration of the suprachiasmatic nucleus, pineal gland, hypothalamus and brain nuclei. Furthermore, it has recently been reported that sleep disorder may accelerate the AD neurodegeneration and cognitive decline (4,5). A previous study has suggested that insufficient sleep facilitates the accumulation of amyloid β (Aβ), which has been confirmed as one of the main pathological characteristics of AD (6). Neurofibrillary tangles composed of an excessive amount of phosphorylated tau (p‑tau) protein have been confirmed as the second pathology of AD. Therefore, Aβ and abnormal tau protein have a central role in the neuropathology of AD (7,8). A previous study has also confirmed that a long tau was associated with the delayed sleep phase disorder, which may be the reflection of an abnormal circadian timing system (9). The interplay and synergy between Aβ and tau induce sleep disorder and accelerate the pathogenesis of AD (10,11).

Sleep is produced when the internal inhibition process spreads to the cerebral cortex and subcortical structure. Sleep serves an essential role in the regulation of synaptic weight in the brain; for instance, it reduces the slow wave activity of the brain caused by the accumulation of synaptic enhancement in wakefulness (12). The neuropeptides orexin A (also known as hypocretin‑1) and orexin neurons express A1 adenosine receptor (A1R) secreted from lateral hypothalamus (LH) neurons are known to be critical modulators of the sleep/wakefulness system (13,14). In addition, it has been reported that orexinergic system disorder may alter the sleep‑wake rhythms and influence AD pathology (15). It has also been reported that blockade of adenosine A1R in the orexinergic
mice were free access to food and water and were kept in an
Technology (Shanghai) Co. Ltd (Shanghai, China) All the
received cerebral injection of Aβ 25‑35 (cat. no. ym‑Y‑0044,
previously described in which 1‑year old 5xFAD mice sponta
the experiments. The AD mouse model was constructed as

Before use, Aβ 25‑35 was diluted in sterile saline to a concen
traction of 0.5 mM and was maintained at 37˚C for 7 days to
pre‑age the peptide (24). The aged Aβ solution was diluted to 40 µM for use.

Sleep analysis. The sleep disturbances and sleep‑wake state of
AD mice were recorded and analyzed with polysomnography,
in which electroencephalogram (EEG) and electromyography (EMG) results were recorded and used to analyzed
the non‑rapid eye‑movement sleep and rapid eye‑movement
sleep. In order to obtain the EEG and EMG scan, EEG and
EMG electrodes were implanted into the skull simultane
ously (NeuroLogger, TSE Systems GmbH, Bad Homburg,
Germany). For EEG recording, two stainless steel screws
attached to wire electrodes were placed over the right frontal
and parietal bones. For EMG recording, two wire electrodes
were directly inserted into the neck musculature.

During the study, age matched mice were used as a control.
Briefly, after 2 days of habituation to the device, 5xFAD
mice and age matched controls underwent EEG recordings,
which commenced on day 3. Body movements, and brain
EEG activity was recorded and stored at 200 samples per
second with a high‑pass filter of 0.25 Hz and low‑pass
filter of 70 Hz. Digitized data were downloaded offline to a
computer. EEG and EMG signals were recorded in a computer
and then assessed with sleep‑scoring software (SIRENIA®
SEIZURE PRO).

Cell culture. The human SH‑SY5Y cell line was purchased
from the American Type Culture Collection (ATCC®
CRL‑2266™; Manassas, VA, USA) and cultured in Eagle's
minimum essential medium (cat. no. M2279; Sigma‑Aldrich;
Merck KGaA, Darmstadt, Germany) supplemented with 10% fetal bovine serum (cat. no. F4135; Sigma‑Aldrich;
Merck KGaA), 100 IU/ml penicillin (cat. no. 10378016;
Gibco; Thermo Fisher Scientific, Inc., Waltham, MA,
USA), 100 mg/ml streptomycin (cat. no. 15140‑122; Gibco;
Thermo Fisher Scientific, Inc.), 1% non‑essential amino acids
(cat. no. 11140‑050; Invitrogen; Thermo Fisher Scientific, Inc.)
and 1% glutamine (cat. no. 11090‑081; Gibco; Thermo Fisher
Scientific, Inc.) at 37°C with 5% CO2. SH‑SY5Y cells were
treated with or without the tau inhibitor TRx 0237. SH‑SY5Y
cells were cultured in 6‑well plates and transfected with vehicle, Aβ 25‑35 or
TRx 0237 for 48 h. Before use, Aβ 25‑35 was diluted in
sterile saline to a concentration of 0.5 mM and was maintained
at 37°C for 7 days to pre‑age the peptide (24). The aged
Aβ solution was diluted to 40 µM for use.
**Oligonucleotide transfection.** Negative control (NC) and small interfering RNAs (siRNAs) targeting adenosine A1R (si-A1R) or orexin A (si-orexin A) were purchased from Shanghai GeneChem Co., Ltd. (Shanghai, China). SH-SY5Y cells (1x10^5 cells/well) were seeded in 6-well plates and transfected with NC, si-A1R or si-orexin A for 48 h using Lipofectamine 3000 reagent (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol.

RNA extraction and reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Mice anesthetized with 400 mg/kg chloral hydrate (i.p.) (23) were decapitated on the day after all the behavioral and neurocognitive tests finished, and the whole brains of which olfactory bundle, optic nerve, cerebellum and medulla were removed were collected and frizzed at -80°C for PCR and western blotting assays. Total RNA from the brain tissues or cells was extracted using TRizol reagent (cat. no. 15596-018; Invitrogen; Thermo Fisher Scientific, Inc.), cDNA was synthesized using 1 µg total RNA and then reverse transcribed to cDNA using an RT assay (DBI Bioscience, Newark, DE, USA). Subsequently, the relative expression of different target genes and controls was analyzed using a SYBR-Green PCR Master Mix kit (cat. no. RR420A; Takara Bio, Inc., Otsu, Japan) and the qPCR reactions were performed on an ABI 7500 Real-Time PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.). The primer sequences for the genes were as follows: Tau, 5'-GTGGCCAGGTGGAAGTAAA-3' (forward) and 5'-TGG AAGACACATTGCTAGG-3' (reverse); orexin A, 5'-GCA TATCGGCGCTTATA-3' (forward) and 5'-GGGTCC TCGAGTCTTTCCTCC-3' (reverse); adenosine A1R, 5'-TTG AGGTGCTTGTGCTAC-3' (forward) and 5'-ATCCTCT GCTTTCTGTG-3' (reverse); GAPDH, 5'-GCC ATC GTAAGCTTTGCC-3' (reverse). Cycling conditions included denaturation at 95°C for 2 min followed by annealing at 94°C for 20 sec for 40 cycles, and extension at 58°C for 20 sec. On the basis of exponential amplification of the target gene as well as a calibrator, the quantity of amplified molecules at the quantification cycle was given by 2^{-ΔΔCq}. The data was assayed with the comparative 2^{-ΔΔCq} method (25) to determine the expression levels of target genes.

**Western blot analysis.** Total proteins from the tissues or cells were lysed in radioimmunoprecipitation assay buffer (Beyotime Institute of Biotechnology, Haimen, China) containing protease inhibitors (BIOSS, Beijing, China), and the protein concentration was determined using a BCA Protein assay kit (Thermo Fisher Scientific, Inc.). Equal amount of total proteins was then separated by 10% SDS-PAGE and transferred onto a polyvinylidene difluoride membrane (cat. no. PK-NEF1002; PerkinElmer, Inc., Boston, MA, USA). Next, fat-free milk (5%) was used to block the membranes for 2 h at room temperature. Following blocking, the membranes were incubated with primary antibodies overnight at 4°C. The blots were subsequently incubated with horseradish peroxidase-conjugated secondary antibodies (1:4,000) at room temperature for 1 h (Wuhan Boster Biological Technology, Ltd., Wuhan, China; cat. no. BA1054) and then developed using an enhanced chemiluminescence detection kit (Thermo Fisher Scientific, Inc.) according to the manufacturer’s protocol. The primary antibodies used included anti-GAPDH (dilution, 1:2,000; ab8245), anti-tau (dilution, 1:1,000; ab10439), anti-p-tau (dilution, 1:1,000; ab4841), anti-A1R (dilution, 1:1,500; ab82477) and anti-orexin (dilution 1:1,500; ab77370; all purchased from Abcam, Cambridge, MA, USA) antibodies.

**Statistical analysis.** The data were analyzed by the Student's t-test and analysis of variance (ANOVA) using IBM SPSS software (version 19.0; IBM Corp., Armonk, NY, USA). The Student-Newman-Keuls post hoc test was used to calculate the P-value for pairwise comparisons following ANOVA. Paired t-test was used to analyze comparisons between the groups and paired data. Unpaired t-test was used to analyze comparisons between 2 groups. Each experiment was repeated at least 3 times. Data are presented as the means ± standard deviation. A statistically significant difference was considered to be denoted by P<0.05.

**Results**

**Decreased non-rapid eye movement (NREM) sleep and increased wakefulness in AD mice.** The sleep patterns in the control and AD groups were compared, and as mice are nocturnal animals, the sleep cycle was from 8 am to 8 pm. The results indicated that the NREM sleep in AD mice was significantly decreased compared with that in the control group (P<0.05, P<0.01 and P<0.001; Fig. 1A). The results also demonstrated that non-rapid eye movement (NREM) sleep in AD mice was similar to the normal amount observed in control animals at other time points, except for at 16:00 (P<0.05) (Fig. 1B). The wakefulness in AD mice at 8:00 was markedly increased compared with that of the control group (P<0.001), however, it was equal to the normal amount of wakefulness observed in control animals at other hourly time points (Fig. 1C).

**Behavioral changes in AD model mice.** The Morris water maze test was applied to confirm the behavioral changes of AD mice. The tracing of the movement of mice during the hidden platform test and the probe trial test for the control and AD model mice are presented in Fig. 2. The results revealed that the escape latency of the hidden platform test was significantly longer in the AD model mice as compared with that in the control mice (P<0.05; Fig. 2A and B). Therefore, it is suggested that the AD model was successfully established in the mice. In addition, the results indicated that the number of platform-crossings for the AD model mice was significantly lower compared with that of the control mice (P<0.05; Fig. 2C and D). It is, thus, suggested that the learning ability of AD model mice was worse in comparison with that of control group mice.

**Upregulation of tau, p-tau, orexin A and adenosine A1R in the brain tissue of 5xFAD mice.** RT-qPCR and western blot analysis were conducted to validate the expression levels of different genes in the control and AD mice. The RT-qPCR results demonstrated that the relative expression levels of tau, orexin A and adenosine A1R were markedly upregulated in the AD model mice compared with those in the control mice (P<0.05; Fig. 3A and B). These results suggested that the AD model mice were successful in replicating the changes observed in the human brain.
AD mice compared with the control mice (P<0.01, P<0.001 and P<0.05, respectively; Fig. 3A). The western blot results were consistent with the RT-qPCR results (Fig. 3B). The tau, p-tau, orexin A and adenosine A1R expression levels were higher in AD mice compared with those in control mice (P<0.05; Fig. 3C).

Treatment with Aβ25-35 upregulates the expression levels of tau, p-tau, orexin A and adenosine A1R in SH-SY5Y cells. RT-qPCR and western blot analysis were also used to detect the mRNA and protein expression levels, respectively, in SH-SY5Y cells treated with Aβ25-35. As shown in Fig. 4, the mRNA expression levels of tau, orexin A and adenosine A1R were significantly increased in Aβ25-35-treated SH-SY5Y cells as compared with the control group cells (P<0.01), while significant increase was also observed in the protein levels of tau, p-tau, orexin A and adenosine A1R.

Changes in mRNA and protein expression levels following treatment with Aβ25-35, or a combination of Aβ25-35 and TRx 0237. There was a significant increase in the mRNA relative expression levels of adenosine A1R and orexin A following Aβ25-35 treatment; however, the high expression levels of adenosine A1R and orexin A were significantly reduced following Aβ25-35 and TRx 0237 co-treatment (P<0.05; Fig. 5A). Next, the protein expression levels of tau, p-tau, orexin A and adenosine A1R were determined by western blot analysis. Overexpression of tau, p-tau, orexin A and adenosine A1R was observed in the Aβ25-35-treated group compared with the control group. However, TRx 0237 co-treatment significantly reversed the promoting effects of Aβ25-35 on tau, p-tau, orexin A and adenosine A1R expression (Fig. 5B and C).

Silencing of adenosine A1R and orexin by siRNA transfection inhibits tau and p-tau expression mediated by Aβ25-35 in SH-SY5Y cells. The current study further explored the effects of adenosine A1R and orexin A knockdown on tau and p-tau expression induced by Aβ25-35 in the AD cell model. As shown in Fig. 6, the results indicated that tau and p-tau
expression levels were significantly upregulated in the Aβ25-35 group compared with the control. However, these levels were significantly downregulated in the Aβ25-35 + si-A1R and Aβ25-35 + si-orexin A groups compared with the Aβ25-35 and Aβ25-35 + NC groups (P<0.05; Fig. 6). Therefore, these data suggested that adenosine A1R or orexin knockdown inhibited the Aβ25-35-mediated expression levels of tau and p-tau in the AD cell model.
Discussion

AD is the most common type of neurodegenerative disease that affects the cognitive functions of the elderly (26). Currently, no therapies are available to halt or reverse the progression of this disease. In the present study, it was observed that NREM sleep was decreased and wakefulness was increased in AD mice. In the Morris water maze assay, a shorter escape latency time indicates better memory, and increased number of platform crossings indicates better learning ability (27,28). The present study in 5xFAD mice revealed a longer escape latency and lower number of platform crossings compared with control group, which indicated a deteriorated memory and learning ability in 5xFAD mice.

Aβ serves a pivotal and potentially causative role in the pathogenesis of AD, and has thus become a major therapeutic target (29). At present, studies have confirmed that AD neurodegeneration started with the aggregation of non-soluble monomeric Aβ peptides, and that the deposition of Aβ in plaques is the main driver of AD pathogenesis. Epidemiological studies have reported that patients with AD suffered from sleep dysfunction (2,30,31). Sleep disorder has been confirmed to decrease clearance of Aβ in the brain and accelerate AD pathology. In the present study, the interaction between sleep disorder and AD was further explored.

In recent years, it has been documented that the aggregation of Aβ can induce abnormal phosphorylation of tau protein and lead to nerve fiber formation (32). In addition, a higher level of tau protein has been confirmed as a marker of rapid cognitive decline, while the abundance of neurofibrillary

![Figure 5](image-url)

Figure 5. Changes in the mRNA and protein expression levels in SH-SY5Y cells following treatment with Aβ25-35 or with a combination of Aβ25-35 and TRx 0237. (A) Gene expression changes for AR1 and orexin A upon treatment with Aβ25-35 or Aβ25-35+TRx 0237. (B) Western blots and (C) quantified values of the protein expression levels of tau, p-tau, orexin A and AR1 following treatment with Aβ25-35 or Aβ25-35+TRx 0237. Each experiment was repeated at least 3 times. *P<0.05, **P<0.01 and ***P<0.001 vs. control group; ##P<0.01, ###P<0.001 vs. Aβ25-35-treated group. p-tau, phosphorylated tau.

![Figure 6](image-url)

Figure 6. Silencing of AR1 and orexin A by siRNA transfection inhibited tau and p-tau expression mediated by Aβ25-35 in the Alzheimer's disease cell model. SH-SY5Y cells were treated with Aβ25-35 and then transfected with NC, si-AR1 or si-orexin A, respectively. Protein expression levels of tau and p-tau were measured by western blot assay and quantified according to the protein gray values in treated SH-SY5Y cells. *P<0.05, **P<0.01 and ***P<0.001 vs. control group; ###P<0.001 vs. Aβ25-35 + NC group. p-tau, phosphorylated tau; siRNA, small interfering RNA.
the abnormal regulation of Aβ and tau on the adenosine A1R can be predicted that the sleep disorder may be associated with decreased sleep in the sleep-wake cycle (16,17). Consequently, it LH induced a significant increase in wakefulness, while it adenosine A1R. Blockade of adenosine A1R in the orexinergic synaptic transmission of orexin neurons via the receptor wakefulness (36,37). Additionally, adenosine inhibits excitatory network of sleep disorder in AD pathology.

The orexinergic system is a key regulator of sleep onset. The neuropeptide orexin A (also known as hypocretin-1) produced by LH neurons has a significant impact on sleep-wake cycle regulation (13,35). It has been suggested that orexin regulated both the diurnal wake and nocturnal sleep periods through reducing REM sleep and slow-wave sleep, and increasing wakefulness (36,37). Additionally, adenosine inhibits excitatory network of sleep disorder in AD pathology.

In conclusion, the present study highlighted that sleep disorder in 5xFAD mice with AD-like neurocognitive changes is positively associated with the accumulation of Aβ and tau, which induced the overactivation of the orexigenic system. Therefore, there are two factors: 1) accumulation of Aβ and tau, which induced the overactivation of the orexigenic system, and 2) the sleep-wake cycle changes. It is also necessary to investigate the deeper mechanisms underlying the actions of adenosine A1R and orexin in sleep disorder in AD.

Acknowledgements
Not applicable.

Funding
No funding was received.

References


